Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry. 2021

Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
Department of Pediatric Pneumology, Immunology and Intensive Care Medicine, Charité - Universitätsmedizin, Berlin, Germany. Electronic address: claudia.grehn@charite.de.

Epidemiology and potential risk factors for cystic fibrosis arthropathy (CFA) were studied in a relevant cystic fibrosis (CF) patient cohort. Cohort study of patients included in the German CF registry in 2016-2017. Descriptive analysis, exploratory tests and multivariable logistic regression were used to assess prevalence of CFA and associated potential risk factors for adult patients with/without chronic Pseudomonas aeruginosa infection. 6069 CF patients aged from 0 to 78 years were analysed. CFA was observed in 4.9% of the patients. Prevalence was significantly higher in adult patients (8.4%) compared to patients <18 years (0.7%; p<0.0001). Logistic regression analyses in adult patients (n=3319) showed that CFA was significantly associated with increasing age (OR=1.04; 95% CI: 1.02-1.05; p<0.0001), female gender (OR=2.10; 95%CI:1.52-2.90; p<0.0001), number of hospitalizations (OR=1.24; 95%CI:1.12-1.36; p<0.0001), chronic P. aeruginosa infection (OR=1.83; 95%CI:1.28-2.61; p=0.0009), CF-related diabetes (OR=1.69; 95%CI:1.23-2.33; p=0.0013), pancreatic insufficiency (OR=2.39; 95%CI:1.28-4.46; p=0.0060) and sinusitis/polyps (OR=1.91; 95%CI:1.39-2.62; p<0.0001). In a subgroup analysis of adults without chronic P. aeruginosa infection (n=1550) CFA was also significantly associated with increasing age, female gender, increasing number of hospitalizations, pancreatic insufficiency as well as sinusitis/polyps; antimycotic treatment associated only in this subgroup while association with CF-related diabetes was not significant. CFA is a frequent and clinically relevant co-morbidity particularly in adult CF patients. CFA is significantly more common in patients with chronic P. aeruginosa colonization but associations with other indicators for a more severe disease course were identified regardless of P. aeruginosa colonization status.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007592 Joint Diseases Diseases involving the JOINTS. Arthropathies,Arthropathy,Joint Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010188 Exocrine Pancreatic Insufficiency A malabsorption condition resulting from greater than 10% reduction in the secretion of pancreatic digestive enzymes (LIPASE; PROTEASES; and AMYLASE) by the EXOCRINE PANCREAS into the DUODENUM. This condition is often associated with CYSTIC FIBROSIS and with chronic PANCREATITIS. Pancreatic Insufficiency,Exocrine Pancreatic Insufficiencies,Insufficiencies, Exocrine Pancreatic,Insufficiencies, Pancreatic,Insufficiency, Exocrine Pancreatic,Insufficiency, Pancreatic,Pancreatic Insufficiencies,Pancreatic Insufficiencies, Exocrine,Pancreatic Insufficiency, Exocrine
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D012042 Registries The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers. Parish Registers,Population Register,Parish Register,Population Registers,Register, Parish,Register, Population,Registers, Parish,Registers, Population,Registry
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children

Related Publications

Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
July 2020, Klinische Padiatrie,
Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
February 2019, Respiratory medicine,
Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
January 1997, Journal of insurance medicine (New York, N.Y.),
Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
September 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
May 2023, ERJ open research,
Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
May 2019, Pediatric diabetes,
Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
August 2021, Acta obstetricia et gynecologica Scandinavica,
Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
September 2018, International journal of environmental research and public health,
Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
February 2020, Pediatric pulmonology,
Claudia Grehn, and A-M Dittrich, and J Wosniok, and F Holz, and S Hafkemeyer, and L Naehrlich, and C Schwarz, and
March 1988, Annals of the rheumatic diseases,
Copied contents to your clipboard!